Breast Cancer
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK4/6 inhibitor Therapy (OPERA-01) (OP-1250-301)
- Details
ClinicalTrials.gov ID:
NCT06016738
Diagnosis Type:
NA
USOR Number:
- Address
,
P: